Nephrology Medical News about renal cell carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon- as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, 06/24/09

Castellano D et al. - Results consistently showed that patients in sunitinib group experienced statistically significantly milder kidney-related symptoms, better cancer-specific HRQoL and general health status (in social utility scores) during the study period as measured by these patient-reported outcome end points. No statistical differences between groups were found on the FACT-G physical well-being subscale or the EQ-5D VAS values.

<< Previous
Acetylcysteine and non-ionic isosmolar contrast-induced...

Next >>
Non-traumatic Ureteral Rupture Despite Initial Normal Appearance...